NASH is a progressive disease on the rise. The global incidence rate is 5.3 per 1000 persons. Studies also point out that people with NASH have a significant risk of developing other complications like HCC, liver cirrhosis, etc. While there are no approved therapies, there are several companies having assets in late-stage development. In this digest, we bring you some of the deals and clinical data readouts in January 2021